N-4'-(6-chloro-2-((3R,3aR,6R,6aR)-6-hydroxyhexahydrofuro[3,2-b]furan-3-yloxy)-3H-imidazo[4,5-b]pyridin-5-yl)biphenyl-4-carbonyl-S,S-dimethylsulfoximide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-4'-(6-chloro-2-((3R,3aR,6R,6aR)-6-hydroxyhexahydrofuro[3,2-b]furan-3-yloxy)-3H-imidazo[4,5-b]pyridin-5-yl)biphenyl-4-carbonyl-S,S-dimethylsulfoximide
• 英文别名: 4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]-N-[dimethyl(oxo)-lambda6-sulfanylidene]benzamide；4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]-N-[dimethyl(oxo)-λ6-sulfanylidene]benzamide
• 化学式: C₂₇H₂₅ClN₄O₆S
• 分子量: 569.038
• InChiKey: RLOSFSRNLSJRQW-LUGTWXOSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] NEW AZABENZIMIDAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'AZABENZIMIDAZOLE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015007669A1

  公开（公告）日：2015-01-22

  The present invention relates to compounds of general formula (I), wherein the group R1, R2, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式（I）的化合物，其中基团R1、R2、X和Y的定义如权利要求书中所述，该化合物具有有价值的药理特性，特别是与AMP-活化蛋白激酶（AMPK）结合并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• NEW AZABENZIMIDAZOLE DERIVATIVES
  申请人：HIMMELSBACH Frank

  公开号：US20150025065A1

  公开（公告）日：2015-01-22

  The present invention relates to compounds of general formula I, wherein the group R 1 , R 2 , X and Y are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式I的化合物，其中基团R1、R2、X和Y的定义如权利要求1中所述，具有有价值的药理特性，特别是与AMP-活化蛋白激酶（AMPK）结合并调节其活性。这些化合物适用于治疗和预防受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• US9492436B2
  申请人：——

  公开号：US9492436B2

  公开（公告）日：2016-11-15